Engflag

Cedax Suspension

Quick links to important sections

Cedax Suspension

Cedax Suspension_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cedax Suspension

Quick Facts

Property Description
Active Ingredient Ceftibuten Dihydrate
Form Suspension for oral administration (liquid)
Pharmacological Class Third-generation cephalosporin antibiotic
General Purpose Broad-spectrum antimicrobial treatment
Origin Synthetic

What Type of Antibiotic is Cedax Suspension?

Cedax Suspension is a prescription-only medicine whose active ingredient is Ceftibuten, supplied as Ceftibuten Dihydrate. Pharmacologically, this compound is consistently classified as a third-generation cephalosporin antibiotic, which belongs to the larger family of beta-lactam antibiotics. Ceftibuten is a synthetic compound, deliberately structured to be a robust, chemically stable agent. This advanced third-generation cephalosporin design gives it a broad-spectrum antimicrobial reach, ensuring it is a reliable single-active ingredient option for addressing a variety of systemic bacterial infections.

Why is Ceftibuten Available as an Oral Suspension?

The pharmaceutical preparation of Cedax Suspension is a liquid dosage form intended for the oral route of administration, typically supplied as a powder mixed into a suspension for oral administration. This specific formulation is a key differentiating factor, making the medicine accessible and easily administered to patient populations that require a non-solid alternative, primarily pediatric patients and others with swallowing difficulties. The formulation consists of the Ceftibuten Dihydrate active ingredient uniformly dispersed within an aqueous suspension base. Pharmacokinetic data support the appropriate bioavailability of this liquid form in children and adolescents.

What is the General Purpose of This Third-Generation Cephalosporin?

The primary general purpose of Cedax Suspension is to provide broad-spectrum antimicrobial treatment by clearing active infections caused by susceptible organisms. Ceftibuten achieves this function through its bactericidal action, meaning it actively kills the harmful microorganisms. This core mechanism directly contributes to its utility as a decisive agent for resolving systemic bacterial infections throughout the body.

What side effects are possible with Cedax Suspension?

Possible Side Effects and Safety Information

Cedax Suspension (ceftibuten) is a prescription antimicrobial agent. Like all medications, it is associated with potential side effects, which are officially documented by governmental regulatory authorities. These effects primarily involve the gastrointestinal and nervous systems.

Adverse Reactions Summary

System-Organ Class Common (1% to 10%) Serious (Incidence not known)
Gastrointestinal Diarrhea, Nausea, Vomiting, Abdominal pain, Dyspepsia Clostridium difficile-associated diarrhea (CDAD) / Pseudomembranous colitis, Melena
Nervous System Headache, Dizziness Seizures (cephalosporin class effect, mainly with renal impairment), Aphasia, Psychosis
Hepatic Increased ALT, Increased Bilirubin Jaundice
Dermatologic Anaphylaxis, Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN)
Hematologic Increased eosinophils, Decreased hemoglobin Hemolytic anemia, Pancytopenia, Neutropenia
Renal Increased BUN Increased Creatinine

Key Safety Considerations

  • Hypersensitivity: The medication is contraindicated in individuals with a known allergy to ceftibuten or to the cephalosporin class of antibiotics. Serious hypersensitivity reactions, including anaphylaxis, require immediate intervention.
  • Gastrointestinal Risk: Use requires caution in patients with a history of gastrointestinal disease, particularly colitis. The development of severe diarrhea, which may occur even months after treatment, should be immediately reported as it may indicate life-threatening CDAD.
  • Renal Function: Since ceftibuten is primarily eliminated by the kidneys, dosage adjustment is mandatory in patients with severe renal impairment (creatinine clearance < 50 mL/min) or those on hemodialysis. Failure to adjust the dose in patients with renal dysfunction may increase the risk of systemic adverse effects, including seizures, which is a known class effect of cephalosporins.
  • Superinfection: Prolonged or repeated use may lead to the overgrowth of non-susceptible organisms, which includes the risk of oral or vaginal candidiasis (moniliasis).

Overdose and Emergency Response

Overdose and when to seek help

The information below summarizes the official, documented risks and required emergency actions associated with an overdose of Cedax Suspension (Ceftibuten Dihydrate).

Overdose Scope

Domain Official Regulatory Statement
Documented Overdose Presentations The primary clinical sign of an overdose is the occurrence of seizures or convulsions, consistent with drug-induced cerebral irritation in the cephalosporin class.
Physiological Systems Affected The Central Nervous System is the system documented to be affected, resulting in neurological sequelae.
Dose-Related Factors Overdose symptoms are typically associated with very high doses, often compounded by impaired drug clearance.
Population-Specific Overdose Notes Patients with severe renal impairment face a heightened risk of accumulation and toxicity because the body’s ability to clear Ceftibuten is significantly reduced.
Emergency-Response Statements Seek emergency medical treatment immediately if an overdose is suspected.
When Immediate Medical Help is Required Call emergency services immediately if the affected individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Resulting Overdose Structure

Official overdose statements:

  • The ingestion of excessive amounts of Ceftibuten may result in seizures or convulsions as a primary manifestation of neurological effects.
  • Management of a suspected overdose is focused on providing symptomatic and supportive treatment.
  • Hemodialysis is a documented procedure that can be used to remove the drug from the bloodstream, with regulatory data confirming its ability to remove approximately 65% of the compound over 2 to 4 hours.
  • There is no specific chemical antidote known; thus, supportive care remains the mandated course of action.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by stating that the primary risk is neurological toxicity, which requires an immediate emergency response. The official management procedures rely on supportive treatment and the use of hemodialysis as a means of drug clearance, which is particularly relevant for the documented high-risk population of patients with renal impairment.

Therapeutic Uses of Cedax Suspension

What Cedax Suspension Treats: Main Uses and Benefits

The therapeutic scope of this medicine is relevant in clinical settings that involve acute or unstable symptom patterns. The medicine is commonly applied in specific clinical contexts based on its therapeutic characteristics.

Cedax Suspension is commonly used to help manage conditions presenting with significant symptomatic burden, including acute bacterial otitis media, pharyngitis and tonsillitis, and acute bacterial exacerbations of chronic bronchitis. It is applied across domains where additional symptomatic support is needed, primarily in pediatric and other patient groups requiring a liquid formulation.

This medication supports the management of distressing symptoms like intensified pain, fever, and discomfort associated with these bacterial illnesses. It contributes to improved comfort during symptomatic periods.

“This medicine is relevant in contexts involving heightened systemic burden and may assist with maintaining a sense of stability.”

Quick Fact: Symptomatic Relief for Acute Discomfort

Domain Focus Symptom Category Patient Benefit
Ear & Throat Pain, Fever, Inflammation Contributes to easing the overall symptom load
Lower Airway Cough, Systemic Discomfort Supports the patient during symptomatic episodes

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Cedax Suspension — Official Regulatory Information

Category Official Regulatory Status
Populations for whom use is allowed: Pediatric patients 6 months of age up to 12 years; Adolescents and Adults (12 years or older).
Populations for whom use is contraindicated: Patients with a known hypersensitivity or allergy to cephalosporin antibiotics.
Age-related eligibility rules: Safety and efficacy have not been established in infants younger than 6 months of age.
Condition-specific eligibility rules: Use is with caution in patients with a history of colitis. The oral suspension contains sucrose, a restriction for patients with diabetes.
Organ Function Restrictions: Patients with moderate to severe renal dysfunction (CrCl 5-49 mL/min) are eligible, but require conditional use and management.
Pregnancy and lactation eligibility status: Pregnancy: Assigned to FDA Pregnancy Category B. Use is permitted only if clearly needed. Lactation: Excreted in human milk in small quantities; regulatory guidance advises caution.

Resulting Eligibility Structure

Official eligibility statements:

  • Use is contraindicated in any patient with a known allergy to the cephalosporin class of antibiotics.
  • The safety and effectiveness of the suspension are not established for infants younger than six months of age.
  • Renal impairment (moderate to severe) defines a restricted population, necessitating official caution and management.

The regulatory documents primarily define eligibility by establishing a clear contraindication based on known hypersensitivity. Eligibility is structurally defined by age boundaries, limiting its established use to those 6 months and older. For populations with specific health conditions, official caution and restriction are applied based on existing organ impairment and certain comorbidities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes specific interaction domains that require caution or monitoring during co-administration.

Interacting Product Category Official Regulatory Constraint/Requirement
Live Bacterial Vaccines Concomitant use with BCG, Cholera, or Typhoid vaccines is generally avoided due to the risk of pharmacodynamic antagonism, which may diminish the vaccine's intended effect.
Anticoagulants The use of Cedax with warfarin or similar anticoagulants requires close clinical monitoring, including INR (International Normalized Ratio) checks, due to the potential for increased bleeding risk.
Oral Contraceptives Official labeling identifies certain oral contraceptives as substances to be considered during co-administration.

Pharmacokinetic interactions are also documented, primarily concerning the absorption of the suspension formulation.

Non-Medicinal Product/Condition Pharmacokinetic Effect & Constraint
Food (Suspension) Administration of the oral suspension with food, including a high-fat meal, decreases the extent of the drug's absorption (AUC and C max). Dosing separation from meals is required to optimize absorption.
Renal Impairment Patients with pre-existing renal dysfunction experience reduced elimination and higher, more sustained drug concentrations. This condition is a population-specific factor noted in the interaction context.

This structure ensures that agents opposing the drug's function (e.g., live vaccines) and those altering its level in the body (e.g., food, renal function) are managed through established procedural constraints.

Mechanism of Action

Ceftibuten, the active ingredient, functions as a third-generation beta-lactam antibiotic that interferes with bacterial cell wall synthesis. Its mechanism involves covalently binding to and inactivating crucial transpeptidases, which are a class of bacterial penicillin-binding proteins (PBPs). These transpeptidases are essential for catalyzing the cross-linking of peptidoglycan chains, which provides structural rigidity to the bacterial cell wall. By inhibiting this transpeptidation step, Ceftibuten prevents the final assembly of the cell wall. This defective assembly leads to structural instability, osmotic lysis, and subsequent death of the bacterial cell. Furthermore, Ceftibuten is chemically stable against hydrolysis by many common plasmid-mediated beta-lactamases, a molecular characteristic that sustains its PBP-inhibitory effect in the presence of these enzymes.

Dosage and Administration Information

Cedax Suspension (ceftibuten dihydrate) is administered orally and must be used according to a standardized, fixed-course protocol. The standard duration of therapy for approved uses is a 10-day course, with administration occurring once daily.

The dosing regimen is based on age or weight. For patients 12 years or older, the standard dose is 400 mg daily. For children 6 months to 11 years, the dosage is determined by weight at 9 mg/kg once daily, with a maximum dose of 400 mg. Safety and usage have not been established for patients younger than 6 months.

A critical procedural requirement for the suspension is its relationship to food intake. The oral suspension must be taken on an empty stomach, meaning administration must occur at least 2 hours before or 1 hour after a meal. Proper use also requires that the suspension be shaken well prior to measurement and the dose be accurately measured with a marked device.

The usage protocol includes specific adjustments for patients with renal impairment. Dose reduction is mandatory based on calculated creatinine clearance, ranging from 200 mg down to 100 mg daily in adults. For patients on hemodialysis, the full dose is administered at the completion of each dialysis session. Following preparation, the liquid must be stored in the refrigerator and discarded after 14 days.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cedax Suspension

Evidence for Use in Acute Bacterial Otitis Media (Ear Infection)

Research examined the use of Cedax Suspension in patients with acute bacterial otitis media, which is a condition characterized by periods of heightened symptom activity, particularly in children. These studies were used in research exploring how outcomes related to physical discomfort, such as pain and fever, change over the short-term treatment interval. Research focused primarily on pediatric patients who may require a liquid formulation. Studies monitored outcomes describing episodic or acute changes in the infection status and monitored the eradication of the susceptible bacteria. Findings describe patterns observed in the studies related to the clinical status of the infection shortly after the treatment course was finished.

Evidence for Use in Pharyngitis and Tonsillitis (Throat Infections)

Clinical trials and systematic reviews explored patient-reported experiences for pharyngitis and tonsillitis, which are conditions involving periods of heightened symptoms. Research evaluated the use of Cedax Suspension in the context of these conditions when caused by susceptible organisms. Studies explored the outcomes related to systemic or functional imbalance, such as fever and discomfort, and monitored the status of bacterial eradication. Short-term study findings describe patterns observed in specific groups, but research does not determine whether an individual will respond similarly to the group patterns reported.

Special Study Focus: The Oral Suspension Formulation

Beyond studies related to specific infections, research has specifically examined the oral suspension formulation itself. Pharmacokinetic studies were conducted to explore how the active ingredient is absorbed, distributed, and eliminated in the body. This research was evaluated in children and adolescents, as this liquid form is available for use in younger patients. Research monitored the absorption patterns of the oral suspension, providing context on how the drug's pharmacokinetic characteristics differ between very young children and older adults.

What is Still Uncertain About Cedax Suspension (Ceftibuten)

The research surrounding the main approved uses focuses primarily on acute changes in conditions. The follow-up durations for these clinical studies were short. Consequently, there is limited information for long-term outcomes, such as patterns of recurrence after the antibiotic course is finished. Comparative evidence against other similar treatments is lacking in some subgroups. Follow-up durations were limited, and more research is ongoing to expand the context of the available evidence.

Key Studies & References

  1. NIH PubMed Study on Ceftibuten Oral Suspension Bioavailability in Children and Adolescents (General Reference)
  2. MedlinePlus Drug Information: Ceftibuten Dihydrate (General Reference for Classification)

Frequently Asked Questions (FAQ)

Common questions about Cedax Suspension (FAQ)

Q: How long does Cedax Suspension typically stay in the body after the last dose?

A: According to official product information, the active ingredient, ceftibuten, is mainly eliminated through the kidneys. The elimination half-life, which describes how quickly the body processes the drug, is typically around 2.5 to 4 hours in adults with normal kidney function.

Q: What are the differences between Cedax Suspension and other cephalosporin antibiotics?

A: Cedax (ceftibuten) is a third-generation cephalosporin. Official information highlights its chemical stability against common beta-lactamase enzymes produced by some bacteria. This stability is a molecular characteristic that supports its activity against certain bacteria.

Q: Why is it important to complete the full course of Cedax Suspension even if symptoms improve?

A: Official patient counseling information advises that the entire course of therapy should be completed. This is generally recommended to help ensure the infection is fully addressed and to reduce the potential for the bacteria to develop resistance to the medicine.

Q: Can Cedax Suspension cause changes in mood or behavior?

A: Official adverse reaction reports for this medication have included effects on the nervous system. Although rare, these have included reports of aphasia (difficulty with language) and psychosis. Other psychiatric effects, such as agitation and irritability, have been noted in clinical trials.

Q: What are the inactive ingredients in Cedax Suspension?

A: Inactive ingredients in the oral suspension include sucrose (about 1 gram per 5 mL), sodium benzoate, cherry flavoring, silicon dioxide, polysorbate 80, simethicone, titanium dioxide, and xanthan gum.

Q: Are there different strengths available for Cedax Suspension?

A: Yes, official prescribing information indicates that the oral suspension is available in two concentrations. These concentrations are typically provided as 90 mg of ceftibuten per 5 mL and 180 mg of ceftibuten per 5 mL.

Q: What precautions should be taken when giving Cedax Suspension to older adults?

A: While specific geriatric problems limiting its use have not been identified, official information highlights the role of kidney function. Dosage adjustments may be necessary if kidney impairment is present. Official information emphasizes managing kidney function to help prevent the drug from accumulating in the body.

Q: Does Cedax Suspension have a strong or unpleasant taste?

A: The oral suspension is manufactured to be cherry flavored. However, official reports have noted that an unusual or unpleasant taste has been reported as an occasional adverse reaction.

Q: Are there any known interactions between Cedax Suspension and herbal supplements?

A: Official regulatory documents do not list interactions with specific herbal supplements. They do, however, advise caution for certain substances that affect the gut, such as multivitamin products containing zinc, which may reduce the drug's absorption.

Q: Does Cedax Suspension interact with common antacids?

A: Regulatory documents advise that multivitamin products containing zinc may interfere with how the body absorbs the drug. Specific interactions with common antacids containing aluminum or magnesium are not typically highlighted in the drug's official prescribing information.

Q: Is it normal to see undigested medicine in stool after taking Cedax Suspension?

A: Official pharmacokinetic studies indicate that ceftibuten is eliminated from the body through both urine and feces. Regulatory information notes that a significant portion of the administered dose, approximately 39%, is recovered in the feces within 24 hours of administration.

Q: Does alcohol consumption affect how Cedax Suspension works?

A: There is no specific warning regarding an interaction between ceftibuten and alcohol listed in the drug's official prescribing information from regulatory agencies.

Q: What are the most common side effects of Cedax Suspension in children?

A: Based on official pediatric clinical trials, the most commonly observed side effects (occurring in 1% or more of patients) were related to the digestive and nervous systems. These frequently reported effects include diarrhea, nausea, vomiting, headache, and abdominal pain.

Q: What are the signs of a non-allergic hypersensitivity reaction to Cedax Suspension?

A: Official documents describe non-allergic skin reactions that have occurred, which can include signs such as a rash, pruritus (itching), and urticaria (hives). These are different from severe, life-threatening allergic reactions.

Q: Is there a generic version of Cedax Suspension available?

A: The brand-name product Cedax has been discontinued. However, regulatory sources confirm that the active ingredient, ceftibuten, is currently available as a generic oral suspension that has been approved by the FDA.

Q: Does Cedax Suspension impact blood sugar levels?

A: A known class effect of cephalosporin antibiotics is the potential to cause a false-positive test result for glucose in the urine. This is noted as a possibility when using certain non-copper reduction tests, which could lead to a result suggesting high blood sugar when it is not actually the case.

Q: Is there any data on the long-term safety of Cedax Suspension?

A: The clinical studies used to support the approved uses of the drug were of a short duration, mainly focusing on acute infection changes. Because of this, official information on long-term outcomes and safety, such as patterns of recurrence, is limited.

How should Cedax Suspension be stored and disposed of?

Storage and Disposal of Cedax Suspension (Ceftibuten)

The medicine's storage requirements differ based on its form. The un-reconstituted powder must be stored at controlled room temperature, specifically between 20 C and 25 C. This powder must be kept away from excess heat, moisture, and light, and it is essential to keep it from freezing.

Once mixed, the liquid reconstituted suspension must be stored in the refrigerator at a temperature between 2 C and 8 C. The suspension is stable for a maximum of 14 days under refrigeration and any unused portion must be discarded after this time. The medication must be kept in its tightly closed original container and stored out of the reach of children. Disposal of unused or expired product should follow applicable local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cedax Suspension found in:

A-Z Index: